NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Florian Hucke, Daniela Lenggenhager et al.|Nature|2021Cited by 1.3k
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY scoreBernhard Scheiner, Matthias Pinter, Katharina Pomej et al.|Journal of Hepatology|2021Cited by 309
Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus SorafenibMatthias Pinter, Wolfgang Sieghart, Florian Hucke et al.|Radiology|2012Cited by 197
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenibMatthias Pinter, Markus Peck‐Radosavljevic, Wolfgang Sieghart et al.|Alimentary Pharmacology & Therapeutics|2011Cited by 73
Prognostic factors in patients with hepatocellular carcinoma treated with SorafenibMatthias Pinter, Markus Peck‐Radosavljevic, Wolfgang Sieghart et al.|Zeitschrift für Gastroenterologie|2011Cited by 4